Jan 17, 2012 | Posted by: roboblogger
You don't want coverage like this : "Biogen CEO Tries to Refill Early-Stage Pipeline He Decimated." That would be George Scangos: . . .Scangos and his research chief eliminated about 17 early-stage drug projects in 2010 and last year to hone the company's focus, leaving it with only about four early-stage compounds.
Comments
Please note by clicking on "Post Comment" you acknowledge that you have read the Terms of Service and the comment you are posting is in compliance with such terms. Be polite. Inappropriate posts may be removed by the moderator. Send us your feedback.